Evidence map›Paper›PMID 30296681›Full record

ArticleVirology2018

Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.

Jin Qiu, Shiwen Peng, Ying Ma, Andrew Yang, Emily Farmer, Max A Cheng, Richard B S Roden, T-C Wu, Yung-Nien Chang, Chien-Fu Hung

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00788164 (A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00788164 phase1completednot on this map

A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3)

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2008 to 2023Enrolled75ConditionsCervical Cancer, Precancerous Condition, HPV Disease, Human PapilomavirusArmsTA-HPV, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, imiquimod
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Jin QiuDepartment of Obstetrics and Gynecology, Tongren Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Shiwen PengDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: speng@jhmi.edu.
Ying MaDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Gynecology and Obstetrics, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong province, China.
Andrew YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: ayang35@jhmi.edu.
Emily FarmerDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: femily1@jhmi.edu.
Max A ChengDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: max.cheng@jhmi.edu.
Richard B S RodenDepartment of Pathology, Department of Gynecology and Obstetrics, and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: roden@jhmi.edu.
T-C WuDepartments of Pathology, Department of Obstetrics and Gynecology, Department of Molecular Microbiology and Immunology, and Department of Oncology. Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: wutc@jhmi.edu.
Yung-Nien ChangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Papivax Biotech Inc., Taipei, Taiwan, ROC.
Chien-Fu HungDepartment of Pathology and Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: chung2@jhmi.edu.
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Mouse modeling of HPV infectionR01CA233486 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU, RODEN, RICHARD BRUCE · 2019 to 2023
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259
6 · The paper itself

Abstract

While both pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV recombinant vaccinia viral vector-based vaccines have elicited HPV-specific CD8+ T cell responses in HPV16/E7-expressing tumor models, and been used as prime-boost regimen to enhance HPV-specific immune responses in humans (NCT00788164), the optimal route of administration for TA-HPV remains unclear. In a preclinical model, we examined the immunogenicity of priming with intramuscular pNGVL4a-Sig/E7(detox)/HSP70 followed by TA-HPV boost through different administration routes. We observed that priming twice with a pNGVL4a-Sig/E7(detox)/HSP70 followed by a single TA-HPV immunization boost through skin scarification generated the strongest antigen-specific CD8+ T cell response in C57BL/6 mice. These data translate to tumor control and prolonged survival of treated mice. Our results provide rationale for future clinical testing of intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine prime, TA-HPV vaccine skin scarification boost immunization regimen for the control of HPV-associated diseases.

Indexed as

Administration, MucosalAnimalsAntigens, ViralCD8-Positive T-LymphocytesFemaleHemangiomaImmunity, CellularImmunization, SecondaryMiceMice, Inbred C57BLPapillomavirus VaccinesVaccines, DNAVaccinia virusAntigens, ViralPapillomavirus VaccinesVaccines, DNAHuman papillomaviruspNGVL4a-Sig/E7(detox)/HSP70Pre-clinical modelTA-HPVTherapeutic HPV vaccine

Identifiers

PMID30296681
PMCPMC6415901
OpenAlexW2895264501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.